NDAORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE2 Generics Approved
Approved
Aug 2002
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
21
Data completeness
4/8 — Partial
PREVACID (lansoprazole) by Takeda is proton pump inhibitors [moa]. Approved for proton pump inhibitor [epc]. First approved in 2002.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVACID (lansoprazole) is an oral proton pump inhibitor approved in 2002 that reduces gastric acid production by inhibiting the H+/K+-ATPase enzyme in parietal cells. It is indicated for acid-reflux disorders, GERD, peptic ulcer disease, and related gastroesophageal conditions. The drug is formulated as an orally disintegrating delayed-release tablet to protect the active ingredient from stomach acid.
LOE Approaching
Declining
PREVACID is in late-stage lifecycle decline with $11M annual spending and faces significant competitive pressure; brand teams are likely focused on defensive positioning and managed care retention rather than growth initiatives.
Mechanism of Action
Proton Pump Inhibitors
Pharmacologic Class:
Proton Pump Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Mar 2026
0GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Sep 2025
523 enrolled
GERD (Gastroesophageal Reflux Disease)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
Started Jun 2025
0Pediatric Gastroesophageal Reflux Disease
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Started May 2023
24 enrolled
Erosive Esophagitis
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Started May 2023
300 enrolled
Coronary Artery Disease
Worked on PREVACID at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.